Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2013

Open Access 01-12-2013 | Research

Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients

Authors: Nicola Bonner, Linda Abetz, Juliette Meunier, Mirko Sikirica, Stephen C Mathai

Published in: Health and Quality of Life Outcomes | Issue 1/2013

Login to get access

Abstract

Background

The Living with Pulmonary Hypertension questionnaire (LPH) was adapted from the Minnesota Living with Heart Failure Questionnaire for use in patients with pulmonary arterial hypertension (PAH). Study objectives were to confirm the face and content validity, to assess the structure and psychometric properties, and provide guidance for the interpretation of the LPH.

Methods

A qualitative interview study was conducted with PAH patients in the US (n=12), Germany (n=14) and France (n=12) to evaluate the face and content validity of the LPH. Psychometric validation was performed using blinded data from a double blind, Phase III, clinical trial (n=196). Validation analyses were performed on baseline and week 12 (visit 6/last visit) data and included evaluation of: item response distributions, quality of completion, construct validity, reliability, clinical validity and responsiveness. Analyses to provide an estimation of the Minimal Important Difference (MID) for the LPH scores were performed.

Results

Cognitive debriefing interviews with 38 PAH patients indicated that the most commonly reported PAH symptoms and impacts are covered by LPH items. Patients found the LPH questionnaire relevant and comprehensive to their experience. Some suggestions were made to enhance the face validity of the LPH. The content validity of the questionnaire was supported. Results of the psychometric validation analyses (n=190) indicated that the LPH Emotional and Physical scores met the criteria for convergent and discriminant validity; for the total score all but two items met the test for item convergent validity. Internal consistency reliability was demonstrated by Cronbach’s alpha values of >0.70 for all LPH scores. The LPH Physical and Total scores discriminated between World Health Organisation (WHO) Functional classes and 6 Minute walk test distances, indicating clinical validity and were also responsive to change in clinical severity, as measured by change in WHO functional class and Borg CR 10 Scale. Further investigation is required to confirm the responsiveness of the Emotional score. Estimation of MID using distribution-based methods indicated a change of 3 points for the sub-scales and 7 for the total score to be clinically meaningful.

Conclusion

The LPH is a valid and reliable instrument that meets FDA criteria.
Appendix
Available only for authorised users
Literature
1.
Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T: Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States. Curr Med Res Opin 2011,27(9):1763–1768. 10.1185/03007995.2011.604310PubMedCrossRef
2.
Rich S: Right ventricular adaptation and maladaptation in chronic pulmonary arterial hypertension. Cardiol Clin 2012,30(2):257–269. 10.1016/j.ccl.2012.03.004PubMedCrossRef
3.
Rich S, Dantzker DR, Ayres SM, et al.: Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987, 107: 216–223. 10.7326/0003-4819-107-2-216PubMedCrossRef
4.
Humbert M, Gerry CJ, Khanna D: Early detection and management of pulmonary arterial hypertension. Eur Respir Rev 2012,21(126):306–312. 10.1183/09059180.00005112PubMedCrossRef
5.
6.
Taichman DB, Shin J, Hud L, et al.: Health-related quality of life in patients with pulmonary arterial hypertension. Respiratory Research 2005, 6: 92–101. 10.1186/1465-9921-6-92PubMedCentralPubMedCrossRef
7.
Doughty N, McKenna SP, Doward LC, Meads DM, Pepke-Zaba J: The Impact of Pulmonary Arterial Hypertension (PAH) on Patients: Results from Qualitative Patient Interviews. Poster Presented at 10th Annual Conference of the International Society for Quality of Life Research (ISOQOL); 2003.
8.
Shafazand S, Goldstein MK, Doyle RM, Hlatky MA, Gould MK: Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004, 126: 1452–1459. 10.1378/chest.126.5.1452PubMedCrossRef
9.
Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP: Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 2009,135(1):137–142. 10.1378/chest.07-0275PubMedCrossRef
10.
Chen H, Taichman DB, Doyle RL: Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thorac Soc 2008,5(5):623–630. 10.1513/pats.200802-020SKPubMedCentralPubMedCrossRef
11.
Chen H, De MT, Kobashigawa EA, Katz PP, Chang VW, Blanc PD: Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension. Eur Respir J 2011,38(3):608–616. 10.1183/09031936.00161410PubMedCentralPubMedCrossRef
12.
McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J: The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Quality of Life Research 2006, 15: 103–115. 10.1007/s11136-005-3513-4PubMedCrossRef
13.
14.
Barst RJ, McGoon M, McLaughlin V, et al.: Berapost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003,41(12):2119–2125. 10.1016/S0735-1097(03)00463-7PubMedCrossRef
15.
Simmonneau G, Barst RJ, Galie N, et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002,165(6):800–804. 10.1164/ajrccm.165.6.2106079CrossRef
16.
Snow JL, Kawut SM: Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy. Clin Chest Med 2007, 28: 75-viii. 10.1016/j.ccm.2006.11.005PubMedCentralPubMedCrossRef
17.
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334: 296–302. 10.1056/NEJM199602013340504PubMedCrossRef
18.
Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, et al.: Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 2005, 171: 1292–1297. 10.1164/rccm.200410-1411OCPubMedCrossRef
19.
Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al.: Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004, 25: 2243–2278.PubMedCrossRef
20.
Sastry BK, Narasimhan C, Reddy NK, Raju BS: Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004, 43: 1149–1153. 10.1016/j.jacc.2003.10.056PubMedCrossRef
21.
Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, et al.: Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006, 114: 1482–1489. 10.1161/CIRCULATIONAHA.106.618397PubMedCrossRef
22.
Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al.: Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005, 46: 529–535. 10.1016/j.jacc.2005.04.050PubMedCrossRef
23.
Lowe B, Grafe K, Ufer C, Kroenke K, Grunig E, Herzog W, et al.: Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 2004, 66: 831–836. 10.1097/01.psy.0000145593.37594.39PubMedCrossRef
24.
25.
Mucke HA: Pulmonary arterial hypertension: on the way to a manageable disease. Curr Opin Investig Drugs 2008, 9: 957–962.PubMed
26.
Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A: A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009, 30: 394–403.PubMedCentralPubMedCrossRef
27.
28.
Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ: Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant 2007,26(2):181–187. 10.1016/j.healun.2006.11.009PubMedCrossRef
29.
Lewis GD, Shar R, Shahzad K: Sildenafil improves excercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007,116(14):1555–1562. 10.1161/CIRCULATIONAHA.107.716373PubMedCrossRef
30.
Cenedese E, Speich R, Dorschner L, et al.: Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 2006,28(4):808–815. 10.1183/09031936.06.00130405PubMedCrossRef
31.
Ulrich S, Speich R, Domenighetti G, et al.: Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open lable study assessing the effect of Bosentan on haemodynamocs, excercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Med Wkly 2007,137(41–42):573–580.PubMed
32.
McLaughlin VV, Archer SL, Badesch DB, et al.: ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009,53(17):1573–1619. 10.1016/j.jacc.2009.01.004PubMedCrossRef
33.
Glaser B, Strauss AL: The Discovery of Grounded Theory: Strategies for Qualitative Research. New Jersey: Aldine de Gruyter; 1967.
34.
Guest G, Bunce A, Johnson L: How many interviews are enough? An experiment with data saturation and variability. Field Methods 2006,18(1):59–82. Sage Publications 10.1177/1525822X05279903CrossRef
35.
36.
Neely G, Ljunggren G, Sylven C, Borg G: Comparison between the Visual Analogue Scale (VAS) and the category ratio scale (CR-10) for the evaluation of leg exertion. Int J Sports Med 1992,13(2):133–136. 10.1055/s-2007-1021244PubMedCrossRef
37.
Borg E: On Percieved Exertion and its Measurement. Sweden: Doctoral Dissertation; 2007.
38.
Rubin LJ: Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004,126(1 Suppl):7S-10S.PubMedCrossRef
39.
Kind P, Brooks R, Rabin R: EQ-5D concepts and methods: a developmental history. The Netherlands: Springer; 2005.CrossRef
40.
Wilke C, Pickard A: Test-Retest Reliability of the EQ-5D Visual Analog Scale across Populations and Conditions. Value In Health 2009,12(3):A30.CrossRef
41.
Cronbach LJ: Coefficient alpha and the internal structure of tests. Psychometrika 1951, 16: 297–334. 10.1007/BF02310555CrossRef
42.
Nunnally JC, Bernstein IH: Psychometric Theory. 3rd ed. ed. New York: McGraw-Hill; 1994.
43.
Guyatt GH, Deyo RA, Charlson M, Levine MN, Mitchell A: Responsiveness and validity in health status measurements : a clarification. J Clin Epidemiol 1989,42(5):403–408. 10.1016/0895-4356(89)90128-5PubMedCrossRef
44.
Ries AL: Minimally clinically important difference for the UCSD shortness of breath questionnaire, Borg scale, and visual analog scale. COPD 2005,2(1):105–110. 10.1081/COPD-200050655PubMedCrossRef
45.
Jaeschke R, Singer J, Guyatt GH: Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989,10(4):407–415. 10.1016/0197-2456(89)90005-6PubMedCrossRef
46.
Stockler MR, Osoba D, Goodwin P, Corey P, Tannock IF: Responsiveness to change in health-related quality of life in a randomized clinical trial: a comparison of the Prostate Cancer Specific Quality Of Life Instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module. European organization for research and treatment of cancer. J Clin Epidemiol 1998,51(2):137–145. 10.1016/S0895-4356(97)00269-2PubMedCrossRef
47.
Khadka J, Gothwal VK, McAlinden C, Lamoureux EL, Pesudovs K: The importance of rating scales in measuring patient-reported outcomes. Health Qual Life Outcomes 2012, 10: 80. 10.1186/1477-7525-10-80PubMedCentralPubMedCrossRef
48.
Rector TS, Kubo SH, Cohn JN: Patients' self-assessment of the congestive heart failure. Part 2: content, reliability and validity of a new measure, the Minnesota living with heart failure questionnaire. Heart Failure 1987,114(1 pt 1):198–209.
49.
Sloan J, Symonds T, Vargas-Chanes D, Fridley B: Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inf J 2003, 37: 23–31.
50.
Cohen J: Statistical power analysis for the behavioral sciences. New York: Academic Press; 1977.
Metadata
Title
Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients
Authors
Nicola Bonner
Linda Abetz
Juliette Meunier
Mirko Sikirica
Stephen C Mathai
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2013
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-11-161

Other articles of this Issue 1/2013

Health and Quality of Life Outcomes 1/2013 Go to the issue

Research

The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease

Retraction Note

Retraction Note: The multiple sclerosis rating scale, revised (MSRS-R): development, refinement, and psychometric validation using an online community

Research

The patient experience with fatigue and content validity of a measure to assess fatigue severity: qualitative research in patients with ankylosing spondylitis (AS)

Research

Health-related quality of life for children with rare diagnoses, their parents’ satisfaction with life and the association between the two

Research

Quality of life in women undergoing urinary diversion for bladder cancer: results of a multicenter study among long-term disease-free survivors

Research

Psychometric properties of the Spanish version of the mindful attention awareness scale (MAAS) in patients with fibromyalgia